AGRN and myasthenia gravis: An engineered agrin, recalcitrant to anti-agrin antibodies, has been used to treat an animal model of MG, and the recombinant agrin fragment improves NMJ morphology (reduced NMJ fragmentation and nerve sprouting), transmission and increased MuSK in animal models of MG [113].